Insider Trading Alert - RJF, DXCM, UMBF, JAH And URS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 4, 2013, 189 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $160.56 to $35,901,027,172.20.

Highlighted Stocks Traded by Insiders:

Raymond James Financial (RJF) - FREE Research Report

Raney Steven M who is President & CEO RJBank at Raymond James Financial bought 129 shares at $41.14 on Dec. 4, 2013. Following this transaction, the President & CEO RJBank owned 17,651 shares meaning that the stake was reduced by 0.74% with the 129-share transaction.

The shares most recently traded at $48.27, up $7.13, or 14.77% since the insider transaction. Historical insider transactions for Raymond James Financial go as follows:

  • 4-Week # shares sold: 40,230
  • 12-Week # shares sold: 40,230
  • 24-Week # shares sold: 40,230

The average volume for Raymond James Financial has been 757,700 shares per day over the past 30 days. Raymond James Financial has a market cap of $6.7 billion and is part of the financial sector and financial services industry. Shares are up 25.36% year-to-date as of the close of trading on Wednesday.

Raymond James Financial, Inc., through its subsidiaries, engages in the underwriting, distribution, trading, and brokerage of equity and debt securities in the United States, Canada, and Europe. The stock currently has a dividend yield of 1.33%. The company has a P/E ratio of 18.6. Currently there are 2 analysts that rate Raymond James Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RJF - FREE

TheStreet Quant Ratings rates Raymond James Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Raymond James Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DexCom (DXCM) - FREE Research Report

Gregg Terrance H who is Ceo at DexCom sold 9,000 shares at $34.51 on Dec. 4, 2013. Following this transaction, the Ceo owned 732,889 shares meaning that the stake was reduced by 1.21% with the 9,000-share transaction.

Balo Andrew K who is SVP, Regulatory and Clinical at DexCom sold 14,268 shares at $34.21 on Dec. 4, 2013. Following this transaction, the SVP, Regulatory and Clinical owned 124,297 shares meaning that the stake was reduced by 10.3% with the 14,268-share transaction.

The shares most recently traded at $35.09, up $0.88, or 2.5% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 32,300
  • 12-Week # shares sold: 32,300
  • 24-Week # shares sold: 32,300

The average volume for DexCom has been 615,900 shares per day over the past 30 days. DexCom has a market cap of $2.5 billion and is part of the health care sector and health services industry. Shares are up 154.45% year-to-date as of the close of trading on Wednesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

UMB Financial Corporation (UMBF) - FREE Research Report

Graves Greg M who is Director at UMB Financial Corporation bought 122 shares at $63.55 on Dec. 4, 2013. Following this transaction, the Director owned 11,792 shares meaning that the stake was reduced by 1.04% with the 122-share transaction.

The shares most recently traded at $61.58, down $1.97, or 3.2% since the insider transaction. Historical insider transactions for UMB Financial Corporation go as follows:

  • 4-Week # shares bought: 146
  • 4-Week # shares sold: 9,475
  • 12-Week # shares bought: 146
  • 12-Week # shares sold: 9,475
  • 24-Week # shares bought: 274
  • 24-Week # shares sold: 20,733

The average volume for UMB Financial Corporation has been 277,400 shares per day over the past 30 days. UMB Financial Corporation has a market cap of $2.8 billion and is part of the financial sector and banking industry. Shares are up 41.44% year-to-date as of the close of trading on Wednesday.

UMB Financial Corporation, through its subsidiaries, offers various banking and other financial services in the United States. The company operates through four segments: Bank, Payment Solutions, Institutional Investment Management, and Asset Servicing. The stock currently has a dividend yield of 1.45%. The company has a P/E ratio of 20.9. Currently there is 1 analyst that rates UMB Financial Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UMBF - FREE

TheStreet Quant Ratings rates UMB Financial Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full UMB Financial Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jarden Corporation (JAH) - FREE Research Report

Franklin Martin E who is Executive Chairman at Jarden Corporation sold 250,000 shares at $55.93 on Dec. 4, 2013. Following this transaction, the Executive Chairman owned 4.1 million shares meaning that the stake was reduced by 5.77% with the 250,000-share transaction.

Ashken Ian G H who is Vice Chairman and CFO at Jarden Corporation sold 37,500 shares at $56.01 on Dec. 4, 2013. Following this transaction, the Vice Chairman and CFO owned 1.0 million shares meaning that the stake was reduced by 3.51% with the 37,500-share transaction.

Lillie James E who is Chief Executive Officer at Jarden Corporation sold 30,000 shares at $56.06 on Dec. 4, 2013. Following this transaction, the Chief Executive Officer owned 527,080 shares meaning that the stake was reduced by 5.39% with the 30,000-share transaction.

Capps John Edward who is EVP, General Counsel and Sec. at Jarden Corporation sold 10,000 shares at $55.84 on Dec. 4, 2013. Following this transaction, the EVP, General Counsel and Sec. owned 120,294 shares meaning that the stake was reduced by 7.67% with the 10,000-share transaction.

The shares most recently traded at $56.15, up $0.31, or 0.55% since the insider transaction. Historical insider transactions for Jarden Corporation go as follows:

  • 12-Week # shares sold: 1,500
  • 24-Week # shares sold: 329,000

The average volume for Jarden Corporation has been 996,000 shares per day over the past 30 days. Jarden Corporation has a market cap of $7.2 billion and is part of the consumer goods sector and consumer durables industry. Shares are up 62.71% year-to-date as of the close of trading on Wednesday.

Jarden Corporation manufactures, markets, and distributes consumer products in the Unites States and internationally. The stock currently has a dividend yield of 1.01%. The company has a P/E ratio of 28.7. Currently there are 7 analysts that rate Jarden Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAH - FREE

TheStreet Quant Ratings rates Jarden Corporation as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, good cash flow from operations, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jarden Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

URS Corporation (URS) - FREE Research Report

Bishop Thomas W who is Senior VP, IE Div at URS Corporation sold 5,000 shares at $51.66 on Dec. 4, 2013. Following this transaction, the Senior VP, IE Div owned 83,385 shares meaning that the stake was reduced by 5.66% with the 5,000-share transaction.

The shares most recently traded at $52.01, up $0.35, or 0.67% since the insider transaction. Historical insider transactions for URS Corporation go as follows:

  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 106,835

The average volume for URS Corporation has been 725,200 shares per day over the past 30 days. URS Corporation has a market cap of $3.9 billion and is part of the services sector and diversified services industry. Shares are up 32.2% year-to-date as of the close of trading on Wednesday.

URS Corporation provides engineering, construction, and technical services to public agencies and private sector clients worldwide. The stock currently has a dividend yield of 1.62%. The company has a P/E ratio of 12.9. Currently there are 2 analysts that rate URS Corporation a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on URS - FREE

TheStreet Quant Ratings rates URS Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full URS Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI